Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Phase
II
Summary
Evaluate the effects of an investigational cell and gene treatment called MB-CART2019.1 on the cancer cells in patients who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL.
Description
Phase II MB-CART2019.1 for R/R DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov